Anti-βS-Globin Antibodies for Specific Sickle Mutation Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for sickle cell disease, such as sickle cell anemia, lack effective methods to detect and address the abnormal sickling of red blood cells caused by the βS-globin mutation, leading to anemia and organ damage.
Innovation Solution
Development of anti-βS-globin antibodies and antigen binding fragments that specifically recognize the Glu6Val mutation in β-globin, enabling detection and potential therapeutic interventions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current treatments for sickle cell disease are used, then general symptom management is provided, but effective detection and addressing of the abnormal sickling caused by βS-globin mutation is lacking
Solution Approach 1:
The patent introduces antibodies as intermediary detection tools that specifically bind to the βS-globin mutation (Glu6Val). These antibodies serve as mediators between the target antigen (sickled β-globin) and detection systems, enabling precise identification of the mutation without directly treating the underlying cause. The antibodies act as specialized probes that bridge the gap between the molecular defect and detectable signal.
2Adaptability or versatility
If general sickle cell treatments are applied, then anemia and organ damage are addressed, but the underlying cause of sickling (βS-globin mutation) cannot be specifically targeted
Solution Approach 1:
The patent applies local quality by designing antibodies with specific binding characteristics tailored to recognize only the βS-globin mutation at the precise location of the Glu6Val change. Rather than using general-purpose treatments, the antibodies are customized to interact with the unique structural features of sickled hemoglobin, providing localized and specific targeting of the pathological variant while leaving normal hemoglobin unaffected.
3Measurement precision
If early diagnosis methods are implemented, then detection accuracy is improved, but the ability to intervene at the molecular level (targeting βS-globin) remains limited
Solution Approach 1:
The patent enables preliminary action by providing detection capabilities that identify the βS-globin mutation before significant disease progression occurs. The antibodies allow for early and specific detection of sickle cell disease at the molecular level, enabling intervention at an earlier stage when treatment may be more effective. This preliminary detection capability precedes and informs subsequent therapeutic decisions.
Data Source
AI summary
The invention provides anti-βS globin antibodies or antigen binding fragments thereof.